A phase III, multicentre, prospective, randomized, assessor-blinded, two-arm, parallel group, therapeutic non-inferiority 3-month clinical trial to compare the efficacy and safety of a generic fixed combination of brinzolamide 10 mg/mL + brimonidine tartrate 2 mg/mL eye drops suspension (Pharmathen) versus SIMBRINZA®/Alcon 10 mg/mL + 2 mg/mL eye drops suspension in the treatment of elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension - Therapeutic equivalence trial between two fixed combination of eye drops suspension

Pharmathen S.A.0 个研究点目标入组 200 人开始时间: 2020年2月13日最近更新: 2020年4月20日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Pharmathen S.A.
入组人数: 200

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•For inclusion in the study subjects should fulfill ALL of the following criteria:
•Female or male outpatients, of any race or ethnicity, aged at least 18 years at the time of signing the ICF
•Patients diagnosed with bilateral or unilateral open-angle glaucoma (including open-angle glaucoma with pseudoexfoliation or pigment dispersion) and/or ocular hypertension for whom, as per the investigator’s clinical judgment, monotherapy provides insufficient IOP reduction
•Patients who are able to safely discontinue use of all ocular hypotensive medication(s) and undergo appropriate washout period
•Mean IOP measurements in at least one (1) eye (the same eye), must be:
•=24 mmHg and =36 mmHg at the 09:00 a.m. time point, and
•=21 and =36 mmHg at the 11:00 a.m. time point at both the Eligibility 1 and Eligibility 2 visits after the required washout of any IOP-lowering medication.
•Mean IOP must be =36 mmHg in both eyes at both time points (09:00 a.m. and 11:00 a.m.) of the two Eligibility visits
•If females of childbearing potential, willingness to use an acceptable form of birth control during the clinical trial
•Patients who are able to comprehend and willing to follow the requirements of the study (including availability on scheduled visit dates)
•Patients who are able to understand and willing to provide voluntary written informed consent before any clinical trial-related procedure is performed.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•Patients who meet ANY of the following criteria will be excluded from the study:
•Females who are pregnant, breast feeding, or planning to become pregnant
•Females of childbearing potential who do not agree to utilize an adequate form of contraception
•Schaffer angle grade <2 in either eye, as measured by gonioscopy (extreme narrow angle with complete or partial closure)
•Central corneal thickness (CCT) >620 µm as measured by pachymetry in either eye
•Cup-to-disk ratio (CDR) >0.80 (horizontal or vertical measurement) in either eye
•Severe central visual field loss (i.e., sensitivity =10 decibel [dB] in at least 2 of the 4 visual field test points closest to the point of fixation) in either eye
•Chronic, recurrent, or current severe inflammatory eye disease (e.g., scleritis, uveitis, herpes keratitis) in either eye
•Ocular infection or ocular inflammation within the past 3 months prior to the Screening visit
•Ocular trauma within the past 6 months prior to the Screening visit
•Clinically significant or progressive retinal disease (e.g., retinal degeneration, diabetic retinopathy, retinal detachment) in either eye
•Other ocular pathology (including severe dry eye) in either eye that may, in the opinion of the Investigator, preclude the safe administration of a topical ocular alpha-adrenergic agonist and/or a topical carbonic anhydrase inhibitor
•Intraocular surgery (e.g., cataract surgery) within the past 6 months prior to the Screening visit
•Refractive surgery, filtering surgery, or laser surgery for IOP reduction within the past 12 months prior to the Screening visit
•Planned ocular surgery of any kind during study participation
•Any abnormality that would prevent accurate IOP readings with the applanation tonometry
•Best corrected visual acuity (BCVA) score worse than 55 ETDRS (Early Treatment Diabetic Retinopathy Study) letters (equivalent to approximately 20/80 Snellen, 0.60 logMAR or 0.25 decimal) in either eye
•Severe illness or other condition that would make the patient, in the opinion of the Investigator, unsuitable for the study
•Patients with severe renal impairment (creatinine clearance [CrCl] <30 mL/min) or hyperchloraemic acidosis
•Current or past history of severe, unstable, or uncontrolled cardiovascular, cerebrovascular, hepatic, or renal disease that would preclude the safe administration of a topical ocular alpha-adrenergic agonist and/or a topical carbonic anhydrase inhibitor, as per the Investigator’s clinical judgment
•Use within 4 weeks prior to the Eligibility 1 visit of:
•systemic corticosteroid
•high-dose (>1 gram daily) salicylate therapy
•monoamine oxidase (MAO) inhibitor therapy
•any antidepressant which affects noradrenergic transmission (e.g., tricyclic antidepressants, mianserin)
•adrenergic-augmenting psychotropic drug (e.g., desipramine, amitriptyline)
•any other medication that augments adrenergic response or precludes use of an alpha-adrenergic agonist
•Use within 2 weeks prior to Eligibility 1 visit of topical ophthalmic corticosteroid or topical corticosteroid
•Use within 6 months prior to Eligibility 1 visit of intravitreal or subtenon injection of ophthalmic corticosteroid
•Use at any time prior to Eligibility 1 visit of intraocular corticosteroid implant
•Patients who currently receive treatment with any investigational drug/device/intervention or who have received any investigational product within 30 days or 5 half-lives of the investigational agent (whichever is longer) before the scree

研究者

发起方

Pharmathen S.A.

相似试验

尚未招募

3 期

A Phase 3, multi-center, prospective, randomized, double-blind, placebo- controlled study to evaluate the effectiveness and safety of ZP5-9676 for the treatment of Hookworm (Ancylostoma duodenale and Necator americanus), Ascaris lumbricoides, and Trichuris trichiura in pediatric and adult ParticipantsSoil-Transmitted Helminthiasis

PACTR202404505131714Zero Point Five Therapeutics300

进行中（未招募）

1 期

A prospective, phase III, multicenter, randomized, investigator-masked, parallel groups, non-inferiority clinical trial for the comparison of efficacy and safety and of a generic fixed combination of Brinzolamide 10mg/ml / Timolol 5 mg/ml eye drops suspension versus Azarga®/ALCON 10mg/ml – 5mg/ml eye drops suspension in subjects with open angle glaucoma or ocular hypertension.open-angle glaucoma or ocular hypertensionMedDRA version: 20.0Level: PTClassification code 10030348Term: Open angle glaucomaSystem Organ Class: 10015919 - Eye disorders

EUCTR2019-000921-39-CYPHARMATHEN SA216

招募中

1 期

A trial that aims to compare the efficacy and safety of two treatments for open-angle glaucoma or ocular hypertension. Both drugs contain the same active substance (Brinzolamide 10 mg/ml Eye Drops, Suspension). The patients will be followed for a certain period of time and will receive on a random principle either the new drug or the authorized drug. The trial will be conducted in several centers. The investigators will not know which patient is using a test and which reference product.

EUCTR2022-002524-12-BGAZAD Pharma AG244

进行中（未招募）

1 期

EUCTR2019-000921-39-GRPHARMATHEN SA216

招募中

1 期

Study to identify the most appropriate therapy for patients with Acute Myeloid Leukemia carrying FLT3 mutation, using the PBC biomarker to customize therapy.Acute Myeloid Leukemia (LMA) with FLT3 mutationMedDRA version: 21.1Level: PTClassification code: 10000880Term: Acute myeloid leukaemia Class: 100000004864

CTIS2023-505901-17-00Fondazione Gimema Franco Mandelli Onlus172